Ann D. Rhoads
Ann D. Rhoads's purchase track record
Ann D. Rhoads has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/10/2025 | QDEL | $21K | -37.4% | -53.1% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
QuidelOrtho Reports Q2 2026 Results and New IR Lead. QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.
Transaction History
| GMED | ▲ Buy | Option Exercise | 25,000 | $657K | 6/4/2026 | View on chart |
| QDEL | ▲ Buy | Grant | 6,829 | $0 | 5/29/2026 | View on chart |
| QDEL | ▲ Buy | Grant | 1,173 | $0 | 5/22/2026 | View on chart |
| QDEL | ▲ Buy | Grant | 234 | $0 | 5/22/2026 | View on chart |
| QDEL | ▲ Buy | Open Market | 750 | $21K | 12/10/2025 | View on chart |
| GMED | ▼ Sell | Open Market | 2,000 | $170K | 11/10/2025 | View on chart |
| GMED | ▼ Sell | Open Market | 8,000 | $648K | 11/7/2025 | View on chart |
| GMED | ▼ Sell | Open Market | 10,000 | $585K | 9/15/2025 | View on chart |
| QDEL | ▲ Buy | Grant | 109 | $0 | 5/24/2025 | View on chart |
| QDEL | ▲ Buy | Grant | 546 | $0 | 5/24/2025 | View on chart |
| QDEL | ▲ Buy | Grant | 4,929 | $0 | 5/22/2025 | View on chart |
| QDEL | ▲ Buy | Grant | 427 | $0 | 5/18/2025 | View on chart |
| QDEL | ▲ Buy | Grant | 128 | $0 | 5/18/2025 | View on chart |
| GMED | ▼ Sell | Open Market | 7,500 | $590K | 2/28/2025 | View on chart |
| GMED | ▲ Buy | Option Exercise | 15,000 | $362K | 9/13/2024 | View on chart |
| GMED | ▲ Buy | Option Exercise | 20,000 | $510K | 9/13/2024 | View on chart |
| GMED | ▼ Sell | Open Market | 15,000 | $1.1M | 9/13/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 1,017 | $0 | 6/6/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 203 | $0 | 6/6/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 2,416 | $0 | 5/24/2024 | View on chart |
| QDEL | ▲ Buy | Grant | 2,248 | $0 | 6/6/2023 | View on chart |
| GMED | ▲ Buy | Option Exercise | 7,500 | $94K | 1/27/2023 | View on chart |
| QDEL | ▲ Buy | Grant | 2,248 | — | 5/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RBC Lowers Globus Medical Price Target to $85
RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.
RBC Lowers Globus Medical Price Target to $85. RBC Capital has lowered its price target for Globus Medical to $85 while maintaining an Outperform rating. This move comes as the company navigates industry challenges, with recent attention on how medical device firms are using generative AI to manage costs and operations. The stock is currently trading below the average analyst target of $100.92, reflecting a cautious outlook from some investors despite the firm's positive stance.